Hansa Biopharma
Hansa Biopharma AB is a commercial-stage biopharmaceutical enterprise headquartered in Lund, Sweden. The company focuses on the development and commercialization of immunomodulatory enzymes for rare immunological diseases and transplant medicine. Its proprietary core technology centers on Imlifidase, an enzyme designed to cleave immunoglobulin G antibodies to enable successful organ transplantation in highly sensitized patients. Principal revenue is derived through commercial pharmaceutical sales of its approved treatments, medical grants, and biopharmaceutical research collaborations. The enterprise serves transplant centers, specialized clinicians, and patients globally. Hansa Biopharma AB is publicly listed on Nasdaq Stockholm.
4 of the funds FundTelligence covers report a position in Hansa Biopharma.
- Legal name
- Hansa Biopharma AB
- Sector
- Health Care
- Country
- Sweden
- Funds holding it
- 4
Funds holding Hansa Biopharma
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.18 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Småbolag Plus — Storebrand · 0.11 % (full portfolio disclosed, October 2026)
- Storebrand Sverige Plus — Storebrand · 0.05 % (full portfolio disclosed, October 2026)
- Lannebo Marknad Sverige Bred — Lannebo · 0.03 % (full portfolio disclosed, June 2026)